Cost-Effectiveness of Office-Based Buprenorphine Treatment for Opioid Use Disorder

Original research
by
Qian, Gary et al

Release Date

2022

Geography

USA

Language of Resource

English

Full Text Available

No

Open Access / OK to Reproduce

No

Peer Reviewed

Yes

Objective

To assess the effectiveness and cost-effectiveness of office-based buprenorphine treatment (OBBT) in the U.S., in terms of fatal and nonfatal overdoses and deaths over five years, discounted lifetime quality-adjusted life years (QALYs), and costs.

Findings/Key points

Using a limited societal perspective that additionally includes patient costs and criminal justice costs, OBBT is cost-saving compared to no treatment even under pessimistic assumptions about efficacy and cost. Expansion of OBBT would be highly cost-effective compared to no treatment when considered from a healthcare perspective, and cost-saving when reduced criminal justice costs are included.

Design/methods

We performed a model-based analysis of buprenorphine treatment provided in a primary care setting for the U.S. population with OUD.

Keywords

Substitution/OAT
Legal system/law enforcement
Overdose
Mortality